A template for provider KAP quantitative survey
Topic(s): Research, Service Delivery
Product(s): Oral PrEP
Population(s): Adolescent Girls and Young Women
Region(s): Sub-Saharan Africa
Format(s): Form/Template
Source(s): OPTIONS
Type: Document
This suite of clinical reporting forms, developed by South Africa’s National Department of Health, can be used for PrEP reporting, including injectable lenacapavir (LEN). The download folder includes forms for PrEP initiation, continuation, pregnancy outcome reporting, and seroconversion reporting.
These country profiles provide concise, actionable snapshots of the HIV prevention and treatment landscape for key populations across multiple countries, including: Brazil, Eswatini, France, Kenya, Malawi, Mozambique, Nigeria, the Philippines, South Africa, Uganda, Ukraine, the United States, Vietnam, Zambia, and Zimbabwe. Country profiles highlight: History of PrEP introduction Updates on PrEP Products Key population epidemiology…
AVAC’s Country Planning for Product Introduction Matrix tracks key indicators for the introduction of new PrEP products, including lenacapavir (LEN), cabotegravir (CAB), and the Dapivirine Vaginal Ring (DVR), by country, including regulatory status, late stage clinical trials and implementation research, procurement plans, and recent oral PrEP provision.
These clinical guidelines, released by the Ukraine Ministry of Health in 2025, include the latest recommendations for HIV services, including oral PrEP and injectable cabotegravir (CAB) for PrEP.
The BLUPrInt PrEP Program Builder breaks down the process of making PrEP – whether oral or injectable – available in your setting into six manageable and coherent program components. Each program component includes a Step-by-Step Guide that presents key decision points and health equity considerations that are crucial to PrEP program development, a templated Standard…
These guidelines, produced in 2022 by the Uganda Ministry of Health, provide guidance on the diagnosis of HIV, the care of people living with HIV, and the use of antiretroviral drugs for treating and preventing HIV infection, including injectable cabotegravir and the dapivirine vaginal ring.
The document, produced by the Malawi Ministry of Health, is a guideline to support funders, implementing partners, district health team leads and service providers in implementing Oral and Long-Acting Injectable PrEP in Malawi.
This toolkit is designed to help clinicians develop knowledge and skills to provide multiple HIV PrEP methods. The toolkit includes resources for oral PrEP, long-acting cabotegravir (CAB-LA), dapivirine vaginal ring (DVR), and long-acting lenacapavir (LEN). Click here to download the full set of additional resources for this training. In October 2025, Jhpiego and WHO held…
This special JIAS supplement illustrates current evidence, implementation learnings and challenges associated with the introduction, uptake, and continued use of PrEP within the context of an expanded HIV prevention method-mix.
Thirteen years after oral PrEP’s introduction, global uptake remains slow, with just over 9 million initiations—falling short of UNAIDS’ 2025 targets. While HIV infections are declining in some regions, others are experiencing increasing epidemics. Despite challenges, lessons from oral PrEP and CAB rollout have strengthened health systems for scaling up longer-acting PrEP. AVAC undertook a…